Thematic Investing Content Hub Capture the Growth Potential in China’s Biotech Sector With This ETF By Ben HernandezDecember 27, 2022
Disruptive Technology Content Hub Biotech Earnings, Market Leap Boost ARKG Potential By Nick Peters-GoldenNovember 11, 2022
Leveraged & Inverse Content Hub Biotech Bounces in August as M&A Activity Increases By Ben HernandezAugust 22, 2022
Thematic Investing Content Hub Capitalize on Biotech Growth in China With This ETF By Ben HernandezJuly 21, 2022
Leveraged & Inverse Content Hub Biotech Belonged to the Bears in Second Half of 2021 By Ben HernandezDecember 25, 2021
Leveraged & Inverse Content Hub Omicron Variant Is Boosting This Leveraged Biotech ETF By Ben HernandezDecember 15, 2021
Nasdaq Investment Intelligence Content Hub How to Invest in Biotech in 2022 By Karrie GordonDecember 15, 2021
Leveraged & Inverse Content Hub This Bearish Biotech ETF Is up 16% in the Past Month By Ben HernandezOctober 12, 2021
Innovative ETFs Content Hub An ETF to Watch for Amidst the Vaccine Push By Ben HernandezAugust 6, 2021
Thematic Investing Content Hub The CHB ETF: China’s Burgeoning Biotech Sector By Ben HernandezMay 7, 2021
Leveraged & Inverse Content Hub Biotech Rose with the Virus. Now It’s Falling Behind By Ben HernandezMarch 19, 2021
Beyond Basic Beta Content Hub IPOs Are Back. Get In On the Action with the BBH ETF By Ben HernandezFebruary 9, 2021
Leveraged & Inverse Content Hub Post-Vaccine Distribution, Mergers Will Dominate Biotech Industry ETFs By Ben HernandezNovember 24, 2020
Beyond Basic Beta Content Hub Bullish on Biotech? The BBH ETF is Not Just a 2020 Play By Ben HernandezNovember 18, 2020
Beyond Basic Beta Content Hub Can’t Get Enough Biotech Exposure in Your Portfolio? By Ben HernandezOctober 29, 2020
Thematic Investing Content Hub China’s Quest for a Covid-19 Vaccine Could Help Boost This ETF By Ben HernandezOctober 19, 2020
Leveraged & Inverse Content Hub Biotech Has Been in a Steady Uptrend Even Through Covid-19 By Ben HernandezAugust 20, 2020
